Key result
Omecamtiv mecarbil and piperine augment cardiac force via distinct crossbridge kinetic mechanisms.
Why the study?
Biochemical and structural assays of myosin states may not provide equivalent measures of myosin recruitment, leaving unclear how these states separately affect contractile force.
Answers are grounded in this paper and cite their sources.
Thick filament activation is primarily a process of myosin recruitment that is not necessarily coupled with crossbridge chemo-cycling, providing insights for the design of sarcomere-based therapies in cardiomyopathies.
Background/Objectives: Thick-filament-based regulation in muscle is generally conceived as processes that modulate the number of myosin heads capable of force generation. It has been generally assumed that biochemical and structural assays of myosin active and inactive states provide equivalent measures of myosin recruitment, but recent studies indicate that this may not always be the case. Here, we studied the steady-state and dynamic mechanical changes in skinned porcine myocardium before and after treatment with omecamtiv mecarbil (OM) or piperine to help decipher how the biochemical and structural states of myosin separately affect contractile force. Methods: Force–Ca2+ relationships were obtained from skinned cardiomyocytes isolated from porcine myocardium before and after exposure to 1 μM OM and 7 μM piperine. Crossbridge kinetics were acquired using a step response stretch activation protocol allowing myosin attachment and detachment rates to be calculated. Results: OM augmented calcium-activated force at submaximal calcium levels that can be attributed to increased thick filament recruitment, increases in calcium sensitivity, an increased duty ratio, and from decelerated crossbridge detachment resulting in slowed crossbridge cycling kinetics. Piperine, in contrast, was able to increase activated force at submaximal calcium levels without appreciably affecting crossbridge cycling kinetics. Conclusions: Our study supports the notion that thick filament activation is primarily a process of myosin recruitment that is not necessarily coupled with the chemo-cycling of crossbridges. These new insights into thick filament activation mechanisms will need to be considered in the design of sarcomere-based therapies for treatment of myopathies.
No takes yet. Share an insight, caveat, or question.
Jani et al. (2025) studied Thick filament regulation and force generation. Omecamtiv mecarbil (OM) and piperine vs. Pre-treatment baseline was evaluated on Crossbridge kinetics (attachment rate 2πb and detachment rate 2πc) and submaximal calcium-activated force. Omecamtiv mecarbil augmented calcium-activated force by increasing thick filament recruitment and slowing crossbridge cycling, whereas piperine increased force without affecting cycling kinetics.
Synapse has enriched 10 related papers. Consider them for comparative context: